Exin Therapeutics vs. Recursion Pharmaceuticals: Choosing Your AI Drug Discovery Partner
Comparing high-density neural activity modeling in mice against industrial-scale automated biology.
Written by Hustlin from public information. Exin Therapeutics hasn’t joined Hustlin.
Exin Therapeutics and Recursion Pharmaceuticals both leverage AI to accelerate drug discovery, but they operate at different scales and biological resolutions. Exin focuses on deep, multimodal neural data from mouse studies to treat brain disorders like epilepsy and Parkinson's. Recursion utilizes a massive, automated platform for broad therapeutic discovery across many indications.
Where Exin Therapeutics is strong
- Proprietary AI models trained on high-density multimodal mouse data generated in-house
- Deep specialization in neural activity modification for epilepsy, autism, and Parkinson's
- Rapid execution with proof-of-concept and two provisional patents within 1.5 months
- Founded and led by Oxford-trained neuroscientists with specialized SAB support
Where Recursion Pharmaceuticals is strong
- Clinical-stage maturity with multiple candidates already in human trials
- Massive industrial-scale automation for experimental biology and imaging
- Broad therapeutic pipeline covering oncology, rare diseases, and more
Side-by-side comparison
| Category | Exin Therapeutics | Recursion Pharmaceuticals | Edge |
|---|---|---|---|
| Primary Data Source | High-density multimodal mouse data | Automated cellular imaging and biology | Neck-and-neck |
| Therapeutic Focus | Neural activity (Brain disorders) | Broad (Oncology, Rare Disease, etc.) | Neck-and-neck |
| Development Stage | Early-stage (Proof-of-concept) | Clinical-stage | Stronger |
| R&D Methodology | AI-directed mouse screening | Industrial-scale automated screening | Neck-and-neck |
| Core Expertise | Oxford-trained Neuroscience | Bio-automation and AI Engineering | Stronger |
Which one should you pick?
Choose Exin Therapeutics if you are focused on neurological disorders where modifying specific neural activity is the primary therapeutic goal.
Choose Recursion Pharmaceuticals if you require a partner with a proven clinical-stage pipeline and massive automated screening capacity across diverse disease areas.
Frequently asked questions
Is Exin Therapeutics better than Recursion?
It depends on the therapeutic goal. Exin is specialized for brain disorders using high-fidelity mouse data, while Recursion is better for broad-scale discovery across many different biological systems.
How is Exin different from Recursion?
Exin focuses on in-vivo neural activity data from mice to guide AI models, whereas Recursion typically uses high-throughput cellular imaging and automated biology at a much larger industrial scale.
When should I use Exin over Recursion?
Use Exin when the target disease is underlined by neural activity dysfunction, such as epilepsy or Parkinson's, and requires specialized neuroscience expertise.
Does Exin have clinical-stage assets?
No, Exin is currently at the proof-of-concept stage in mice, whereas Recursion has several assets in clinical trials.
What is the main advantage of Exin's approach?
Exin's advantage lies in the density and quality of its multimodal mouse data, which allows for more precise modeling of complex brain activity compared to simplified cellular models.
Accelerate Your Neuro-Discovery
Leverage Oxford-trained expertise and AI-driven mouse studies for your next therapeutic breakthrough.
Learn More About ExinBuilding something?
Create a free Hustlin account. Your first Ship Day includes a campus invite, a blog post, and social posts with real URLs.
Create your free account